Directives 90/385/EEC, 93/42/EEC and 98/79/EC contain provisions on a European databank for medical devices which require the establishment of that databank.

"toll" means a specified amount payable for a vehicle based on the distance travelled on a given infrastructure and comprising an infrastructure charge and/or an external cost charge; (ba) "infrastructure charge" means a charge levied through a toll for the purpose of recovering the costs related to infrastructure incurred by a Member State or more than one Member State if the infrastructure project has been jointly undertaken ; (bb) "external cost charge" means a charge levied through a toll for the purpose of recovering the costs incurred by a Member State related to traffic-based air pollution and traffic-based noise pollution ; (bc) "cost of traffic-based air pollution" means the cost of the damage caused by ...[+++]the release of certain harmful air emissions in the course of the operation of a vehicle; (bd) "cost of traffic-based noise pollution" means the cost of the damage caused by the noise emitted by a vehicle or created by the interaction of a vehicle and the road surface; (be) "weighted average infrastructure charge" means the total revenue of an infrastructure charge over a given period divided by the number of vehicle kilometres travelled on the road sections subject to the charge during that period; (bf) "weighted average external cost charge" means the total revenue of an external cost charge over a given period divided by the number of vehicle kilometres travelled on the road sections subject to the charge during that period;

"toll" means a specified amount payable for a vehicle based on the distance travelled on a given infrastructure and comprising an infrastructure charge and/or an external cost charge; (ba) "infrastructure charge" means a charge levied through a toll for the purpose of recovering the costs related to infrastructure incurred by a Member State or more than one Member State if the infrastructure project has been jointly undertaken ; (bb) "external cost charge" means a charge levied through a toll for the purpose of recovering the costs incurred by a Member State related to traffic-based air pollution and traffic-based noise pollution ; (bc) "cost of traffic-based air pollution" means the cost of the damage caused by ...[+++]the release of certain harmful air emissions in the course of the operation of a vehicle; (bd) "cost of traffic-based noise pollution" means the cost of the damage caused by the noise emitted by a vehicle or created by the interaction of a vehicle and the road surface; (be) "weighted average infrastructure charge" means the total revenue of an infrastructure charge over a given period divided by the number of vehicle kilometres travelled on the road sections subject to the charge during that period; (bf) "weighted average external cost charge" means the total revenue of an external cost charge over a given period divided by the number of vehicle kilometres travelled on the road sections subject to the charge during that period;

In many cases the transmission of personal data by the judiciary, police or customs to private parties is necessary to prosecute crime or to prevent an immediate and serious threat to public security or to prevent serious harm to the rights of individuals, for example, by issuing alerts concerning forgeries of securities to banks and credit institutions, or, in the area of vehicle crime, by communicating personal data to insurance companies in order to prevent illicit trafficking in stolen motor vehicles or to improve the conditions f ...[+++]or the recovery of stolen motor vehicles from abroad.

– Centralised information and/or common material systems should be set up, one example being registration of data on new biomedicines, including clinical trial data and information on subsequent approval (for instance comments on adverse reactions), comparison with pharmacogenetic data (correlating genetic specificity with individual reactions to drugs), patient databanks, or central tissue banks;

set up centralised information and/or common material systems, employing procedures such as registration of data on new biotechnological drugs and genetic testing, including clinical trial data and information connected with the subsequent approval stage (for instance notes on adverse reactions), comparison with pharmacogenomic data (correlating specific genetic features with individual reactions to drugs), or the organisation of patient databanks or the development of central tissue banks;